Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)
about
Healthcare quality in systemic lupus erythematosus: using Donabedian’s conceptual framework to understand what we knowCurrent and emerging treatment options in the management of lupusHydroxychloroquine-related retinal toxicityIdentification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agentsEmerging therapies for systemic lupus erythematosus--focus on targeting interferon-alphaViolacein Treatment Modulates Acute and Chronic Inflammation through the Suppression of Cytokine Production and Induction of Regulatory T CellsPrimary cardiac disease in systemic lupus erythematosus patients: protective and risk factors--data from a multi-ethnic Latin American cohort.Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institutionPossible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United StatesAngiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohortCardiovascular involvement in autoimmune diseases.Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohortHydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus.Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosusSystemic lupus erythematosus: review of synthetic drugs.Update on systemic lupus erythematosus pregnancyComprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differencesMaternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupusPrognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort.Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block.Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohortIncidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosusAccelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditionsHydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patientsSystemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohortCardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.Predictors of major infections in systemic lupus erythematosus.Lupus nephritis in children - 10 years' experience.Premature vascular damage in systemic lupus erythematosus.Thrombosis in systemic lupus erythematosus: risk and protection.Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.
P2860
Q24613829-FD4067EB-0A42-4B28-8BC0-4450A2BDFF22Q26741266-71880804-AA32-495F-95E9-AC41521DAEC3Q26782822-FFA3EB47-0097-4510-8290-E08570618CEDQ27302392-203FAF01-9A6A-4D7E-AC88-DA68DDFF2AC6Q28265144-4154310D-7660-4944-9712-B4E91492DC8EQ28546985-71481889-484B-4488-B969-A19D96F74599Q30778909-B166BC6B-C81B-4210-BD12-BA9736562D44Q31129756-097FFF46-8D56-483A-903C-CEA5C510FA47Q33422958-E5838A3D-EF20-4B4B-86C5-70F99B35B444Q33448450-A077BA34-969E-435B-BBEF-2D01ABF3E36BQ33455990-E39A380E-31ED-47C9-9158-B47A2D9E1E97Q33497970-D2623D62-45FE-41FC-B48F-847685489DF3Q33555419-62963C58-D36C-498A-904B-0C8F292A4EAAQ33945242-89C3877E-90FB-48A0-8C51-1E8938B60D29Q34044918-95C59B87-5CA0-42F6-9044-593F061F6018Q34081242-ADF84AF3-2C17-43AA-9468-BCAB3D8948D2Q34161393-6F2467B1-C2CE-4864-8E9D-17659BF24C3BQ34162739-FFB330D1-8C9F-4226-9D03-AFC84D72510CQ34338929-0A476B08-DAE2-44AA-9015-359B6377D49CQ34498515-B75F11D3-6D07-4FFF-A1FB-F897F5EAA585Q35756117-009FEE66-A3A4-4326-B6BD-98E5CEF4B6E0Q36152835-24E56AF2-906B-4A8E-A3CB-6FC34EF11C5BQ36220831-DD2D0A48-EB69-422E-AB9F-1DF15C47B56DQ36234766-113482DB-D9F8-4ED4-AC22-EE62D6972212Q36240425-D90B56F8-94AD-4CDB-8FB4-B0DE91B411E1Q36307429-0D85077C-9F42-42E6-8015-6088EA5810B9Q36551073-6D1AEE93-2A3D-416E-8522-6424E3EEAB95Q36573884-CCC81B46-C1A2-4363-86ED-DF7A12C76719Q36606667-73DAB646-5DB2-4762-B736-0135E76EAA9EQ36746012-F98B5541-5924-4AE8-BC45-549AF9B428D8Q36906782-F655926C-1E0D-449F-B98D-E3C619AB38D9Q37033345-80C97AD4-4170-4CCB-AB9C-7E4CB3B5A71AQ37137299-DB96BFAD-D3BB-4F70-B064-B43B93C3DCE4Q37330468-053E5699-574C-4213-ABBC-C371CA5653CEQ37350893-5C0B63DD-A8C4-4E6E-AD48-81D324F508FBQ37399315-5C115424-928A-42F2-9E7F-DBD4A1136C95Q37573524-D7E34D5C-6B28-4347-BCDF-93ACBB4CD94DQ37642828-9D657DEE-4603-4506-968E-E821691572ABQ37854742-5FC5500D-3AAC-420D-B608-5C4C149E1F72Q37883018-002851C6-8A40-49A8-AEBE-2935354131BF
P2860
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Effect of hydroxychloroquine o ...... ltiethnic US cohort (LUMINA L)
@ast
Effect of hydroxychloroquine o ...... ltiethnic US cohort (LUMINA L)
@en
type
label
Effect of hydroxychloroquine o ...... ltiethnic US cohort (LUMINA L)
@ast
Effect of hydroxychloroquine o ...... ltiethnic US cohort (LUMINA L)
@en
prefLabel
Effect of hydroxychloroquine o ...... ltiethnic US cohort (LUMINA L)
@ast
Effect of hydroxychloroquine o ...... ltiethnic US cohort (LUMINA L)
@en
P2093
P2860
P356
P1476
Effect of hydroxychloroquine o ...... ltiethnic US cohort (LUMINA L)
@en
P2093
Barri J Fessler
Gerald McGwin
Graciela S Alarcón
Holly M Bastian
Jaime Calvo-Alén
LUMINA Study Group
Luis M Vilá
P2860
P304
P356
10.1136/ARD.2006.068676
P407
P577
2007-03-27T00:00:00Z